Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer’s disease: a BeDeCo survey

Acta Neurologica Belgica

Volumn 115, Issue 4, 2015, Pages 547-555

  Bier, Jean Christophe ^a   Verschraegen, Jurn ^b   Vandenberghe, Rik ^c   Guillaume, Bénédicte ^d   Picard, Gaëtane ^e   Otte, Georges ^a   Mormont, Eric ^f   Gilles, Christian ^g   Segers, Kurt ^h   Sieben, Anne ⁱ   Thiery, Evert ⁱ   Ventura, Manfredi ^j   De Deyn, Peter ^a   Deryck, Olivier ^k   Versijpt, Jan ^l   Salmon, Eric ^m   Engelborghs, Sebastiaan ^n,o   Ivanoiu, Adrian ^p  

^a ERASME HOSPITAL   (Belgium)

^b Vlaanderen vzw   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Centre Hospitalier du Bois de l'Abbaye et de Hesbaye   (Belgium)

^e Clinique Saint Pierre of Ottignies   (Belgium)

^f UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^g Vivalia   (Belgium)

^h BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j Grand Hopital de Charleroi   (Belgium)

^k AZ Sint Jan Brugge Oostende   (Belgium)

^l UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^m UNIVERSITY OF LIÈGE   (Belgium)

ⁿ UNIVERSITY OF ANTWERP   (Belgium)

^o Memory Clinic   (Belgium)

^p CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

more..

Author keywords

Alzheimer disease; Biomarkers; Diagnosis criteria; Expert opinion; Survey

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ARTICLE; DISEASE COURSE; HEALTH CARE SURVEY; HUMAN; MILD COGNITIVE IMPAIRMENT; MOTOR DYSFUNCTION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; QUESTIONNAIRE; RISK FACTOR; BELGIUM; DIAGNOSTIC IMAGING; FEMALE; HEALTH SURVEY; MALE; MEDICINE; METABOLISM; PROCEDURES; RETROSPECTIVE STUDY; STANDARDS;

ALZHEIMER DISEASE; BELGIUM; BIOMARKERS; DIAGNOSTIC IMAGING; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MEDICINE; MILD COGNITIVE IMPAIRMENT; RETROSPECTIVE STUDIES;

EID: 84942054071     PISSN: 03009009     EISSN: 22402993     Source Type: Journal    
DOI: 10.1007/s13760-014-0423-7     Document Type: Article

References (21)

1. Boller F, Forbes MM (1998) History of dementia and dementia in history: an overview. J Neurol Sci 158(2):125–133
2. Jack CR Jr, Albert MS, Knopman DS et al (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:257–262
3. Petersen RC, Smith GE, Waring SC et al (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:03–08
4. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183–194
5. Dubois B, Feldman HH, Jacova C et al (2010) Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 9:1118–1127
6. Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13:614–629
7. Sperling RA, Aisen PS, Beckett LA et al (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):280–292
8. Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:270–279
9. McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269
10. Jiha GA, Rentz DM (2013) Cognitive and brain reserve and the diagnosis and treatment of preclinical Alzheimer disease. Neurology 80:1–2
11. Jack CR, Wiste HJ, Lesnick TG et al (2013) Brain β-amyloid load approaches a plateau. Neurology 80:890–897
12. Vuoksimaa E, Panizzon MS, Chen CH et al (2013) Cognitive reserve moderates the association between hippocampal volume and episodic memory in middle age. Neuropsychologia 51(6):1124–1131
13. Montine TJ, Phelps CH et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123:1–11
14. Jack CR Jr, Holtzman DM (2013) Biomarker modeling of Alzheimer’s disease. Neuron 80(6):1347–1358
15. Bennett DA, Schneider JA, Arvanitakis Z et al (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66(12):1837–1844
16. Vandenberghe R, Adamczuk K, Dupont P et al (2013) Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer’s disease. Neuroimage Clin 2:497–511
17. Biomarkers definitions working group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89–95
18. Scheltens P, van der Pol L (2012) Impact commentaries. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 83(11):1038–1040
19. Frisoni GB, Fox NC, Jack CR Jr et al (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6(2):67–77
20. Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55(3):306–319
21. Vandenberghe R, Van Laere K, Ivanoiu A et al (2010) 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 68:319–329